Ranivisio is a biosimilar of Lucentis which treats serious retinal diseases.

Kymab Ltd presents the utility of mice models for studying human immune response to complex vaccines.

Why is Moderna suing Pfizer and BioNTech over its COVID-19 vaccine despite recent pledge?

This Commentary article explores the applications of mRNA therapeutics in disease treatment and prevention. The commercial presence of microfluidics technologies has improved process development, and has helped to provide rapid development along with the existence of established formulation principles for vaccines.

We interview Vincent Dewar, Associate Director and Head of Immunoassay Analytical Research Development at GlaxoSmithKline, to learn more about the importance of immunoassays for vaccine development.

We interview Martin Akerman, Chief Technology Officer and Co-Founder at Envisagenics to find out about machine learning for drug target discovery in RNA.

The 2021 report is in, but who made the cut?

Vyepti is the first intravenous medication approved for migraine treatment.

With influenza expected to make a return this winter, vaccine manufacturers may be facing more demand than usual.

Children between one and nine years old to be given polio jab to curb the spread of the virus throughout the city.